A citation-based method for searching scientific literature

M C Mathieu, S Koscielny, M L Le Bihan, M Spielmann, R Arriagada. Lancet 1995
Times Cited: 33







List of co-cited articles
196 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


p53 protein overexpression and chemosensitivity in breast cancer.
A Makris, T J Powles, M Dowsett, C Allred. Lancet 1995
47
69

Mutant p53 protein associated with chemosensitivity in breast cancer specimens.
O Koechli, G N Schaer, B Seifert, R Hornung, U Haller, U Eppenberger, H Mueller. Lancet 1994
56
54

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.
S W Lowe, H E Ruley, T Jacks, D E Housman. Cell 1993
51

p53 status and the efficacy of cancer therapy in vivo.
S W Lowe, S Bodis, A McClatchey, L Remington, H E Ruley, D E Fisher, D E Housman, T Jacks. Science 1994
51

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
D C Allred, G M Clark, R Elledge, S A Fuqua, R W Brown, G C Chamness, C K Osborne, W L McGuire. J Natl Cancer Inst 1993
753
30

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
T Aas, A L Børresen, S Geisler, B Smith-Sørensen, H Johnsen, J E Varhaug, L A Akslen, P E Lønning. Nat Med 1996
643
30

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
R M Elledge, R Gray, E Mansour, Y Yu, G M Clark, P Ravdin, C K Osborne, K Gilchrist, N E Davidson, N Robert. J Natl Cancer Inst 1995
94
27


Thymocyte apoptosis induced by p53-dependent and independent pathways.
A R Clarke, C A Purdie, D J Harrison, R G Morris, C C Bird, M L Hooper, A H Wyllie. Nature 1993
24

Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
S Fan, M L Smith, D J Rivet, D Duba, Q Zhan, K W Kohn, A J Fornace, P M O'Connor. Cancer Res 1995
554
24

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
A Makris, T J Powles, M Dowsett, C K Osborne, P A Trott, I N Fernando, S E Ashley, M G Ormerod, J C Titley, R K Gregory,[...]. Clin Cancer Res 1997
127
21


p53 is required for radiation-induced apoptosis in mouse thymocytes.
S W Lowe, E M Schmitt, S W Smith, B A Osborne, T Jacks. Nature 1993
21


Gain of function mutations in p53.
D Dittmer, S Pati, G Zambetti, S Chu, A K Teresky, M Moore, C Finlay, A J Levine. Nat Genet 1993
824
18

Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity.
R D Petty, I A Cree, L A Sutherland, E M Hunter, D P Lane, P E Preece, P E Andreotti. Biochem Biophys Res Commun 1994
64
18

Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.
Y Remvikos, P Beuzeboc, A Zajdela, N Voillemot, H Magdelénat, P Pouillart. J Natl Cancer Inst 1989
163
15

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
H B Muss, A D Thor, D A Berry, T Kute, E T Liu, F Koerner, C T Cirrincione, D R Budman, W C Wood, M Barcos. N Engl J Med 1994
901
15

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
B A Gusterson, R D Gelber, A Goldhirsch, K N Price, J Säve-Söderborgh, R Anbazhagan, J Styles, C M Rudenstam, R Golouh, R Reed. J Clin Oncol 1992
799
15

p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
S Fan, W S el-Deiry, I Bae, J Freeman, D Jondle, K Bhatia, A J Fornace, I Magrath, K W Kohn, P M O'Connor. Cancer Res 1994
433
15

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.
S Rozan, A Vincent-Salomon, B Zafrani, P Validire, P De Cremoux, A Bernoux, M Nieruchalski, A Fourquet, K Clough, V Dieras,[...]. Int J Cancer 1998
151
15

Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
D S Hawkins, G W Demers, D A Galloway. Cancer Res 1996
317
15

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.
A F Wahl, K L Donaldson, C Fairchild, F Y Lee, S A Foster, G W Demers, D A Galloway. Nat Med 1996
640
15

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
E M Berns, J A Foekens, R Vossen, M P Look, P Devilee, S C Henzen-Logmans, I L van Staveren, W L van Putten, M Inganäs, M E Meijer-van Gelder,[...]. Cancer Res 2000
143
15

The p53 tumor suppressor gene in breast cancer.
R M Elledge, D C Allred. Breast Cancer Res Treat 1994
133
15

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
D C Allred, G M Clark, A K Tandon, R Molina, D C Tormey, C K Osborne, K W Gilchrist, E G Mansour, M Abeloff, L Eudey. J Clin Oncol 1992
443
12


p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
P C Clahsen, C J van de Velde, C Duval, C Pallud, A M Mandard, A Delobelle-Deroide, L van den Broek, T M Sahmoud, M J van de Vijver. J Clin Oncol 1998
143
12

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D J Slamon, W Godolphin, L A Jones, J A Holt, S G Wong, D E Keith, W J Levin, S G Stuart, J Udove, A Ullrich. Science 1989
12


Prognostic significance of TP53 alterations in breast carcinoma.
T I Andersen, R Holm, J M Nesland, K R Heimdal, L Ottestad, A L Børresen. Br J Cancer 1993
172
12

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.
E Niskanen, C Blomqvist, K Franssila, P Hietanen, V M Wasenius. Br J Cancer 1997
75
12

P53 expression in breast cancer.
G Cattoretti, F Rilke, S Andreola, L D'Amato, D Delia. Int J Cancer 1988
524
12

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.
K V Chin, K Ueda, I Pastan, M M Gottesman. Science 1992
813
12

Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.
T Fujiwara, E A Grimm, T Mukhopadhyay, W W Zhang, L B Owen-Schaub, J A Roth. Cancer Res 1994
485
12

p53 mutations in human cancers.
M Hollstein, D Sidransky, B Vogelstein, C C Harris. Science 1991
12

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
D Kandioler-Eckersberger, C Ludwig, M Rudas, S Kappel, E Janschek, C Wenzel, H Schlagbauer-Wadl, M Mittlböck, M Gnant, G Steger,[...]. Clin Cancer Res 2000
214
12

Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
V Rusch, D Klimstra, E Venkatraman, J Oliver, N Martini, R Gralla, M Kris, E Dmitrovsky. Cancer Res 1995
164
12



Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
P Hietanen, C Blomqvist, V M Wasenius, E Niskanen, K Franssila, S Nordling. Br J Cancer 1995
43
9


Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
A D Thor, I I Moore DH, S M Edgerton, E S Kawasaki, E Reihsaus, H T Lynch, J N Marcus, L Schwartz, L C Chen, B H Mayall. J Natl Cancer Inst 1992
822
9


Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
R Silvestrini, S Veneroni, E Benini, M G Daidone, A Luisi, M Leutner, A Maucione, R Kenda, R Zucali, U Veronesi. J Natl Cancer Inst 1997
89
9

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.
M E Lippman, J C Allegra, E B Thompson, R Simon, A Barlock, L Green, K K Huff, H M Do, S C Aitken, R Warren. N Engl J Med 1978
308
9

Tritiated thymidine labeling index and response in human breast cancer.
A Sulkes, R B Livingston, W K Murphy. J Natl Cancer Inst 1979
85
9


Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
9

p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
R Silvestrini, E Benini, M G Daidone, S Veneroni, P Boracchi, V Cappelletti, G Di Fronzo, U Veronesi. J Natl Cancer Inst 1993
262
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.